In addition, FGFR4 is overexpressed in metastases derived from luminal A breast cancers compared to the primary tumor [47] and high FGFR4 expression and hotspot mutations occur in endocrine therapy-treated distant breast cancer metastases, particularly derived from invasive lobular carcinoma [28]. This evidence concerns the gene FGFR4 and neoplasm.